Clene, Inc. (CLNN)
4.05
-0.11
(-2.64%)
USD |
NASDAQ |
Sep 03, 13:40
Clene Research and Development Expense (TTM) : 11.48M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.48M |
| March 31, 2026 | 11.52M |
| December 31, 2025 | 12.66M |
| September 30, 2025 | 12.72M |
| June 30, 2025 | 13.68M |
| March 31, 2025 | 14.31M |
| December 31, 2024 | 18.68M |
| September 30, 2024 | 19.77M |
| June 30, 2024 | 21.24M |
| March 31, 2024 | 23.67M |
| December 31, 2023 | 25.22M |
| September 30, 2023 | 26.43M |
| Date | Value |
|---|---|
| June 30, 2023 | 27.07M |
| March 31, 2023 | 29.78M |
| December 31, 2022 | 31.10M |
| September 30, 2022 | 32.81M |
| June 30, 2022 | 32.52M |
| March 31, 2022 | 29.85M |
| December 31, 2021 | 27.54M |
| September 30, 2021 | 22.45M |
| June 30, 2021 | 20.30M |
| March 31, 2021 | 17.38M |
| December 31, 2020 | 14.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 3.297M |
| Summit Therapeutics, Inc. | 568.74M |
| Kezar Life Sciences, Inc. | 23.12M |
| Protara Therapeutics, Inc. | 52.89M |